Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 5, 2011, Pages 1171-1179

  Hodeify, Rawad ^a   Tarcsafalvi, Adel ^a,b   Megyesi, Judit ^a,b   Safirstein, Robert L ^a,b   Price, Peter M ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Cell death

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE 2; MUTANT PROTEIN; PROTEIN P21; PURVALANOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 79955769997     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00507.2010     Document Type: Article

References (67)

1. WAF1/Cip1 in monocytic differentiation. EMBO J 18: 1223-1234, 1999.
2. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, Shimizu E, Tsien JZ, Schultz PG, Rose MD, Wood JL, Morgan DO, Shokat KM. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407: 395-401, 2000.
3. Cip1 in S phase. J Biol Chem 278: 25752-25757, 2003.
4. Carroll SB, Grenier JK, Weatherbee SD. From DNA to Diversity: Molecular Genetics and the Evolution of Animal Design. Malden, MA: Blackwell, 2005.
5. Child ES, Mann DJ. The intricacies of p21 phosphorylation: protein/ protein interactions, subcellular localization and stability. Cell Cycle 5: 1313-1319, 2006.
6. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, Sun P, Tan CK, Hengst L, Slingerland J. p27 Phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 26: 281-294, 2007.
7. Collins MO. Evolving cell signals. Science 325: 1635-1636, 2009.
8. Darzynkiewicz Z, Li X, Gong J. Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol 41: 15-38, 1994.
9. Dash BC, El-Deiry WS. Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 25: 3364-3387, 2005.
10. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73: 499-511, 1993.
11. Ernest S, Bello-Reuss E. Expression and function of P-glycoprotein in a mouse kidney cell line. Am J Physiol Cell Physiol 269: C323-C333, 1995.
12. Ewen ME, Faha B, Harlow E, Livingston DM. Interaction of p107 with cyclin A independent of complex formation with viral oncoproteins. Science 255: 85-87, 1992.
13. Faha B, Ewen ME, Tsai LH, Livingston DM, Harlow E. Interaction between human cyclin A and adenovirus E1A-associated p107 protein. Science 255: 87-90, 1992.
14. Giaccone G. Clinical perspectives on platinum resistance. Drugs 59: 9-17, 2000.
15. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ. p21Waf1/Cip1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14: 929-935, 1997.
16. Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 26: 269-280, 2007.
17. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
18. Kip2 in cyclindependent kinase 2 inhibition and growth suppression. J Biol Chem 273: 16544-16550, 1998.
19. He TC, Zhou S, Da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998.
20. Cip1. Genes Dev 12: 3882-3888, 1998.
21. Hoang AT, Cohen KJ, Barrett JF, Bergstrom DA, Dang CV. Participation of cyclin A in Myc-induced apoptosis. Proc Natl Acad Sci USA 91: 6875-6879, 1994.
22. Hodeify R, Megyesi J, Tarcsafalvi A, Safirstein RL, Price PM. Protection of cisplatin cytotoxicity by an inactive cyclin-dependent kinase. Am J Physiol Renal Physiol 299: F112-F120, 2010.
23. Holt LJ, Tuch BB, Villén J, Johnson AD, Gygi SP, Morgan DO. Global analysis of Cdk1 substrate phosphorylation sites provides insights into evolution. Science 325: 1682, 2009.
24. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol 21: 140-146, 2009.
25. Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol 28: 498-510, 2008.
26. Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol 26: 2430-2440, 2006.
27. Jaumot M, Estanol JM, Casanovas O, Grana X, Agell N, Bachs O. The cell cycle inhibitor p21CIP is phosphorylated by cyclin A-CDK2 complexes. Biochem Biophys Res Commun 241: 434-438, 1997.
28. Kip1 puzzle. Cell 26: 241-244, 2007.
29. Cip1 by phosphorylation. J Biol Chem 277: 29792-29802, 2002.
30. Kumar NV, Eblen ST, Weber MJ. Identifying specific kinase substrates through engineered kinases and ATP analogs. Methods 32: 389-397, 2004.
31. Cip/WAF1 and promotes cell survival. J Biol Chem 277: 11352-11361, 2002.
32. Lin JF, Chen QX, Tian HY, Gao X, Yu ML, Xu GJ, Zhao FK. Stain efficiency and MALDI-TOF MS compatibility of seven visible staining procedures. Anal Bioanal Chem 390: 1765-1773, 2008.
33. WAF1/CIP1/SDI1 after acute renal failure. Am J Physiol Renal Fluid Electrolyte Physiol 271: F1211-F1216, 1996.
34. WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 101: 777-782, 1998.
35. WAF1/CIP1 on the course of ischemic acute renal failure. Kidney Int 60: 2164-2172, 2001.
36. Meikrantz W, Gisselbrecht S, Tam SW, Schlegel R. Activation of cyclin A-dependent protein kinase during apoptosis. Proc Natl Acad Sci USA 91: 3754-3758, 1994.
37. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13: 261-291, 1997.
38. Morgan DO. Principles of CDK regulation. Nature 9: 131-134, 1995.
39. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007, 2008.
40. Park DS, Levine B, Ferrari G, Greene LA. Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci 17: 8975-8983, 1997.
41. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287: 821-828, 1999.
42. Price PM, Safirstein RL, Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol Renal Physiol 286: F378-F384, 2004.
43. Price PM, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein RL, Megyesi J. Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J Am Soc Nephrol 17: 2434-2442, 2006.
44. Price PM, Safirstein RL, Megyesi J. The cell cycle and acute kidney injury. Kidney Int 76: 604-613, 2009.
45. Rosenblatt J, Gu Y, Morgan DO. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci USA 89: 2824-2828, 1992.
46. Cip1 regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 21: 5644-5657, 2001.
47. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382: 325-331, 1996.
48. Safirstein R, Portilla D, Luxon B, Gorenstein D, Megyesi J, Price P. Functional genomics in cisplatin nephrotoxicity. J Am Soc Nephrol 13: 327A, 2002.
49. Scott MT, Ingram A, Ball KL. PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumor modifier protein. EMBO J 21: 6771-6780, 2002.
50. Waf1/Cip1 modulates proliferating cell nuclear antigen binding. J Biol Chem 275: 11529-11537, 2000.
51. Shah K, Shokat KM. A chemical genetic approach for the identification of direct substrates of protein kinases. Methods Mol Biol 233: 253-271, 2003.
52. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22: 1567-1572, 2004.
53. Kip1. Genes Dev 11: 1464-1478, 1997.
54. Shi L, Chen G, He D, Bosc DG, Litchfield DW, Greenberg AH. Granzyme B induces apoptosis and cyclin A-associated cyclin-dependent kinase activity in all stages of the cell cycle. J Immunol 157: 2381-2385, 1996.
55. Songyang Z, Blechner S, Hoagland N, Hoekstra MF, Piwnica-Worms H, Cantley LC. Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr Biol 4: 973-982, 1994.
56. Tal M, Silberstein A, Nusser EJ. Why does coomassie brilliant blue r interact differently with different proteins? A partial answer. J Biol Chem 260: 9976-9980, 1985.
57. Tan CS, Pasculescu A, Lim WA, Pawson T, Bader GD, Linding R. Positive selection of tyrosine loss in metazoan evolution. Science 325: 1686-1688, 2009.
58. Tuch BB, Li H, Johnson AD. Evolution of eukaryotic transcription circuits. Science 319: 1797-1799, 2008.
59. Van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262: 2050-2054, 1993.
60. Kip1. EMBO J 16: 5334-5344, 1997.
61. Wang J, Walsh K. Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science 273: 359-361, 1996.
62. Wray GA, Hahn MW, Abouheif E, Balhoff JP, Pizer M, Rockman MV, Romano LA. The evolution of transcriptional regulation in eukaryotes. Mol Biol Evol 20: 1377-1419, 2003.
63. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505-514, 1992.
64. Yu F, Megyesi J, Safirstein RL, Price PM. Involvement of the CDK2- E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo. Am J Physiol Renal Physiol 293: F52-F59, 2007.
65. WAF1/CIP1 that protects cells from cisplatin cytotoxicity. Am J Physiol Renal Physiol 289: F514-F520, 2005.
66. Zhou BB, Li H, Yuan J, Kirschner MW. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc Natl Acad Sci USA 95: 6785-6790, 1998.
67. Zhu H, Nie L, Maki CG. Cdk2-dependent inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem 280: 29282-29288, 2005.